<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02382679</url>
  </required_header>
  <id_info>
    <org_study_id>14D.529</org_study_id>
    <nct_id>NCT02382679</nct_id>
  </id_info>
  <brief_title>Vitamin Therapy in Concussion Management: A Randomized Control Trial</brief_title>
  <official_title>Vitamin Therapy in Concussion Management: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rothman Institute Orthopaedics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of vitamin therapy in concussion when
      compared to placebo with respect to multiple endpoints including symptom severity, cognitive
      performance on computer based neuropsychological testing, post-concussion balance assessment,
      and post-concussion vestibular-oculomotor function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, very little data exists on the use of vitamin supplementation to aid in the recovery
      of concussion. Data previously published shows potential benefit of certain vitamins in the
      management of migraine headache. These vitamins, Vitamin B2 (Riboflavin), Magnesium,
      Co-Enzyme Q-10, and Omega-3 fatty acids, at dosages described in the literature, are being
      used based on the migraine literature findings and anecdotal evidence to help treat
      complaints of headache in concussion management.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCSI: Post-Concussion Symptom Inventory</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Concussion</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Vitamin Mixture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin coenzyme Q10, magnesium, riboflavin and omega-3-fatty acid combination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Experimental: Vitamin Mixture</intervention_name>
    <description>Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids</description>
    <arm_group_label>Experimental: Vitamin Mixture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects ages 11-22

          -  Concussion within 7 days of enrollment

          -  Presenting for treatment at Rothman Institute or Jefferson Concussion Center

        Exclusion Criteria:

          -  Subjects with recent prior concussion within the past 30 days

          -  Subjects with a history of moderate to severe TBI requiring hospitalization or
             resulting in prolonged symptoms (&gt;3weeks).

          -  Subjects with known neurologic diagnosis associated with impaired cognitive function
             other that Attention Deficit Hyperactive Disorder or Attention Deficit Disorder.

          -  Subjects with know allergy to algae, omega-3 fatty acid, or any component of the
             formulation.

          -  Subjects currently requiring anticoagulants (ie- Warfarin), anti-platelets (ie-
             Aspirin, Plavix), or any non-steroidal anti-inflammatory drugs (ie- Ibuprofen,
             Naprosyn).

          -  Subjects with known liver pathology or significantly elevated liver function tests
             (greater than 3 X normal).

          -  Subjects with a current lower extremity injury that will affect postural stability
             testing.

          -  Subjects who are pregnant and/or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Stache, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rothman Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mijail Serruya, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Franks, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rothman Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeremy Close, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <reference>
    <citation>SÃ¡ndor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005 Feb 22;64(4):713-5.</citation>
    <PMID>15728298</PMID>
  </reference>
  <reference>
    <citation>Schiapparelli P, Allais G, Castagnoli Gabellari I, Rolando S, Terzi MG, Benedetto C. Non-pharmacological approach to migraine prophylaxis: part II. Neurol Sci. 2010 Jun;31 Suppl 1:S137-9. doi: 10.1007/s10072-010-0307-4. Review.</citation>
    <PMID>20464605</PMID>
  </reference>
  <reference>
    <citation>Esposito M, Carotenuto M. Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study. Neurol Sci. 2011 Feb;32(1):79-81. doi: 10.1007/s10072-010-0411-5. Epub 2010 Sep 25.</citation>
    <PMID>20872034</PMID>
  </reference>
  <reference>
    <citation>Bianchi A, Salomone S, Caraci F, Pizza V, Bernardini R, D'Amato CC. Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis. Vitam Horm. 2004;69:297-312. Review.</citation>
    <PMID>15196887</PMID>
  </reference>
  <reference>
    <citation>Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S; American Academy of Neurology Quality Standards Subcommittee; Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004 Dec 28;63(12):2215-24. Review.</citation>
    <PMID>15623677</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2015</study_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

